ORIGINAL RESEARCH article

Front. Cell. Infect. Microbiol.

Sec. Veterinary and Zoonotic Infection

Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1619660

This article is part of the Research TopicEmerging and re-emerging vector-borne diseases: A global challengeView all 3 articles

Genomic characterization and antibiotic susceptibility of biofilm-forming Borrelia afzelii and Borrelia garinii from patients with erythema migrans

Provisionally accepted
  • 1Department of Biology and Biotechnology "C. Darwin" Sapienza University of Rome, Rome, Italy
  • 2Microbiology and Virology, San Gallicano Dermatological Institute IRCCS, Rome, Italy
  • 3Laboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Rome, Italy
  • 4Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

The final, formatted version of the article will be published soon.

Background: Borrelia afzelii and Borrelia garinii are the leading causes of Lyme borreliosis (LB) in Europe. Persistent LB forms may involve biofilms, potentially contributing to antibiotic tolerance. Methods: Whole genome sequencing (WGS) was conducted on 7 B. afzelii and 5 B. garinii isolates from erythema migrans skin biopsies. Biofilms were analyzed for extracellular DNA (eDNA) content and biomass. A phenol red metabolic assay assessed the minimum inhibitory concentration (MIC) and minimum biofilm inhibitory concentration (MBIC) of amoxicillin, azithromycin, ceftriaxone, and doxycycline. Results: Phylogenetic analysis revealed B. afzelii and B. garinii formed distinct clades, while B. burgdorferi B31 clustered separately. Core genome analysis showed 38.9% of genes were shared between B. afzelii and B. garinii, decreasing to 26.1% with B. burgdorferi. The cloud genome expanded from 34.4% to 53.4% with the addition of B. burgdorferi.No antimicrobial resistance genes were detected. Surface adhesion gene profiles exhibited significant variation across species, suggesting potential functional differences in host adaptation. B. afzelii and B. garinii species exhibited biofilms, with biomass correlating significantly with eDNA production. MIC values were 0.25 μg/mL (amoxicillin, ceftriaxone), 0.125 μg/mL (azithromycin), and 0.5 μg/mL (doxycycline), with no significant interspecies differences. However, MBIC values were considerably higher: 2 μg/mL (amoxicillin, azithromycin), 16 μg/mL (ceftriaxone), and 32 μg/mL (doxycycline). Conclusions: Biofilms in B. afzelii and B. garinii significantly reduce antibiotic efficacy, particularly ceftriaxone and doxycycline. These in vitro findings highlight the need for targeted therapeutic strategies and suggest biofilms may impact treatment outcomes in LB.

Keywords: Lyme Disease, Borrelia afzelii, Borrelia garinii, Skin, Erythema migrans, Biofilm

Received: 28 Apr 2025; Accepted: 18 Jun 2025.

Copyright: © 2025 Fabrizio, CAVALLO, Sivori, Truglio, Kovacs, Francalancia, D'agosto, Trento, Prignano, Mastrofrancesco, Ružić-Sabljić, PIMPINELLI and Di Domenico. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: ILARIA CAVALLO, Microbiology and Virology, San Gallicano Dermatological Institute IRCCS, Rome, Italy

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.